Eleni Gkika1, Dominik Bettinger2,3, Leo Krafft4, Michael Schultheiss2, Hannes Philipp Neeff5, Lars Maruschke6, Michaela Schulenburg7, Sonja Adebahr4, Simon Kirste4, Ursula Nestle4,8,9,10, Robert Thimme2, Anca-Ligia Grosu4,8,9,10, Thomas Baptist Brunner4,8,9,10. 1. Department of Radiation Oncology, University Medical Center Freiburg, Robert-Koch-Str. 3, 79106, Freiburg im Breisgau, Germany. eleni.gkika@uniklinik-freiburg.de. 2. Department of Gastroenterology, Hepatology, Endocrinology and Infectious Diseases, University Medical Center Freiburg, Freiburg, Germany. 3. Berta-Ottenstein-Programme, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 4. Department of Radiation Oncology, University Medical Center Freiburg, Robert-Koch-Str. 3, 79106, Freiburg im Breisgau, Germany. 5. Department of General and Visceral Surgery, University Medical Center Freiburg, Freiburg, Germany. 6. Department of Radiology, University Medical Center Freiburg, Freiburg, Germany. 7. Department of Nuclear Medicine, University Medical Center Freiburg, Freiburg, Germany. 8. Partner site Freiburg, German Cancer Consortium (DKTK), Freiburg, Germany. 9. Faculty of Medicine, University of Freiburg, Freiburg, Germany. 10. German Cancer Research Center (DKFZ), Heidelberg, Germany.
Abstract
PURPOSE: We evaluated the prognostic accuracy of the albumin-bilirubin (ALBI) grade and the inflammation-based index (IBI) in estimating overall survival (OS) and toxicity in patients with hepatocellular carcinoma (HCC) treated with stereotactic body radiotherapy (SBRT). MATERIALS AND METHODS: Forty patients with 47 HCC lesions with a Barcelona Clinic Liver Cancer (BCLC) classification stage B or C were treated with SBRT in 3-12 fractions. The ALBI grade and the IBI were calculated at different time points (baseline, during, at the end of treatment and at follow-up) and compared with the Child-Pugh (CP) score as well as other patient- and treatment-related parameters, concerning OS and toxicity. RESULTS: The median follow-up was 14.3 months for patients alive. The median OS from SBRT was 10 (95% confidence interval 8.3-11.6) months. The local control at 1 year was 79%. A lower IBI during treatment was associated with better OS (p = 0.034) but not CP and ALBI. Higher C‑reactive protein levels as well as higher alpha-fetoprotein concentrations correlated with worse survival (p = 0.001). Both higher ALBI (p = 0.02) and CTP (p = 0.001) at baseline correlated with a higher incidence of acute and late toxicities (CTC ≥2). Neither the mean radiation dose to the liver nor the dose to 700 cc of the liver correlated with the occurrence of toxicities. CONCLUSIONS: In this analysis, a higher ALBI grade as well as a higher CP were predictors of higher incidence of toxicity, whereas a lower IBI during treatment correlated with a better OS. These results should be further evaluated in prospective studies.
PURPOSE: We evaluated the prognostic accuracy of the albumin-bilirubin (ALBI) grade and the inflammation-based index (IBI) in estimating overall survival (OS) and toxicity in patients with hepatocellular carcinoma (HCC) treated with stereotactic body radiotherapy (SBRT). MATERIALS AND METHODS: Forty patients with 47 HCC lesions with a Barcelona Clinic Liver Cancer (BCLC) classification stage B or C were treated with SBRT in 3-12 fractions. The ALBI grade and the IBI were calculated at different time points (baseline, during, at the end of treatment and at follow-up) and compared with the Child-Pugh (CP) score as well as other patient- and treatment-related parameters, concerning OS and toxicity. RESULTS: The median follow-up was 14.3 months for patients alive. The median OS from SBRT was 10 (95% confidence interval 8.3-11.6) months. The local control at 1 year was 79%. A lower IBI during treatment was associated with better OS (p = 0.034) but not CP and ALBI. Higher C‑reactive protein levels as well as higher alpha-fetoprotein concentrations correlated with worse survival (p = 0.001). Both higher ALBI (p = 0.02) and CTP (p = 0.001) at baseline correlated with a higher incidence of acute and late toxicities (CTC ≥2). Neither the mean radiation dose to the liver nor the dose to 700 cc of the liver correlated with the occurrence of toxicities. CONCLUSIONS: In this analysis, a higher ALBI grade as well as a higher CP were predictors of higher incidence of toxicity, whereas a lower IBI during treatment correlated with a better OS. These results should be further evaluated in prospective studies.
Authors: Charlie C Pan; Brian D Kavanagh; Laura A Dawson; X Allen Li; Shiva K Das; Moyed Miften; Randall K Ten Haken Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Michael Velec; Carol R Haddad; Tim Craig; Lisa Wang; Patricia Lindsay; James Brierley; Anthony Brade; Jolie Ringash; Rebecca Wong; John Kim; Laura A Dawson Journal: Int J Radiat Oncol Biol Phys Date: 2017-02-01 Impact factor: 7.038
Authors: Shaelyn Culleton; Haiyan Jiang; Carol R Haddad; John Kim; Jim Brierley; Anthony Brade; Jolie Ringash; Laura A Dawson Journal: Radiother Oncol Date: 2014-06-03 Impact factor: 6.280
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Hidenori Toyoda; Paul B S Lai; James O'Beirne; Charing C Chong; Sarah Berhane; Helen Reeves; Derek Manas; Richard P Fox; Winnie Yeo; Frankie Mo; Anthony W H Chan; Toshifumi Tada; Mercedes Iñarrairaegui; Arndt Vogel; Nora Schweitzer; Stephen L Chan; Bruno Sangro; Takashi Kumada; Philip J Johnson Journal: Br J Cancer Date: 2016-03-29 Impact factor: 7.640
Authors: Eleni Gkika; Iosif Strouthos; Simon Kirste; Sonja Adebahr; Michael Schultheiss; Dominik Bettinger; Ralph Fritsch; Volker Brass; Lars Maruschke; Hannes Philipp Neeff; Sven Arke Lang; Ursula Nestle; Anca-Ligia Grosu; Thomas Baptist Brunner Journal: Strahlenther Onkol Date: 2018-10-23 Impact factor: 3.621